These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17603308)

  • 1. Adjuvant chemotherapy of stage I non-small cell lung cancer in North America.
    Gandara DR; Wakelee H; Calhoun R; Jablons D
    J Thorac Oncol; 2007 Jul; 2(7 Suppl 3):S125-7. PubMed ID: 17603308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Lung cancer].
    Fischer B; Buhl R
    Med Klin (Munich); 2008 May; 103(5):311-20. PubMed ID: 18484217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
    J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of adjuvant chemotherapy in NSCLC (stages I to III).
    Coleman MH; Bueno R
    Surg Oncol Clin N Am; 2011 Oct; 20(4):757-67. PubMed ID: 21986270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in chemotherapy of non-small cell lung cancer.
    Molina JR; Adjei AA; Jett JR
    Chest; 2006 Oct; 130(4):1211-9. PubMed ID: 17035458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy for surgically resected non-small cell lung cancer.
    Heon S; Johnson BE
    J Thorac Cardiovasc Surg; 2012 Sep; 144(3):S39-42. PubMed ID: 22502967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.
    Socinski MA; Stinchcombe TE; Moore DT; Gettinger SN; Decker RH; Petty WJ; Blackstock AW; Schwartz G; Lankford S; Khandani A; Morris DE
    J Clin Oncol; 2012 Nov; 30(32):3953-9. PubMed ID: 23045594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma.
    Higginson DS; Chen RC; Tracton G; Morris DE; Halle J; Rosenman JG; Stefanescu M; Pham E; Socinski MA; Marks LB
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e385-92. PubMed ID: 22857887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant treatment of stage IB NSCLC: the problem of stage subset heterogeneity.
    Calhoun R; Jablons D; Lau D; Gandara DR
    Oncology (Williston Park); 2008 Apr; 22(5):511-6; discussion 516, 521-3. PubMed ID: 18533401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developments in the treatment of non-small cell lung cancer.
    Gkiozos I; Charpidou A; Syrigos K
    Anticancer Res; 2007; 27(4C):2823-7. PubMed ID: 17695454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer.
    Visbal AL; Leighl NB; Feld R; Shepherd FA
    Chest; 2005 Oct; 128(4):2933-43. PubMed ID: 16236970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
    Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N
    Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab in non small cell lung cancer.
    Sandler A
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4613-6. PubMed ID: 17671151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
    Klein R; Wielage R; Muehlenbein C; Liepa AM; Babineaux S; Lawson A; Schwartzberg L
    J Thorac Oncol; 2010 Aug; 5(8):1263-72. PubMed ID: 20581708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
    Merk J; Rolff J; Becker M; Leschber G; Fichtner I
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):454-9. PubMed ID: 19502076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further?
    Wozniak AJ; Gadgeel SM
    Oncology (Williston Park); 2007 Feb; 21(2):163-71; discussion 171, 174, 179-82. PubMed ID: 17396481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Consolidation therapy in advanced non-small cell lung cancer].
    Duchnowska R
    Pneumonol Alergol Pol; 2010; 78(6):439-44. PubMed ID: 21077036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical treatment of non-small-cell lung cancer.
    Buter J; Giaccone G
    Ann Oncol; 2005; 16 Suppl 2():ii229-32. PubMed ID: 15958463
    [No Abstract]   [Full Text] [Related]  

  • 20. Erlotinib-based perioperative adjuvant therapy for a case of unresectable stage IIIA (N2) nonsmall cell lung cancer.
    Wang Q; Wang H; Li P; Zhu H; He C; Wei B; Ma J; Ma Z
    Am J Med Sci; 2010 Oct; 340(4):321-5. PubMed ID: 20601859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.